The Short-term Efficacy And Safety Of Drug-eluting Bead Transarterial Chemoembolization In The Treatment Of Advanced Primary Liver Cancer

Objective: To compare the Short-term efficacy and safety of drug-eluting bead transarterial chemoembolization in the treatment of advanced primary liver cancer.Methods: The patients with advanced primary liver cancer admitted to the interventional therapy department of the Guangxi medical university affiliated cancer hospital from January 2017 to March 2018 were collected retrospectively.according to the inclusion and exclusion criteria of this study,88 patients with advanced primary liver cancer were strictly selected and included in this study.the patients were divided into 2 groups according to the surgical treatment plan accepted by the patients,44 of whom received drug-eluting bead transarterial chemoembolization(DEB-TACE group).Another 44 patients received conventional arterial chemoembolization(CTACE group).the adverse reactions,tumor necrosis rate,objective response rate,disease control rate and AFP changes before and after TACE were compared between the two groups.Among them,the focus is to compare the degree of postoperative tumor tissue necrosis between the two groups.Results: 4-6 weeks after TACE,the necrosis rate of the two groups was72%±20% vs 47%±10%,the difference was statistically significant(P<0.05).The ORR of DEB-TACE group was higher(P=0.003),and the difference was statistically significant compared with CTACE group.Although DCR in DEB-TACE group is higher than that in CTACE group,there is no statistical difference(P=0.796).After interventional therapy,abdominal pain,fever,nausea,vomiting,anorexia and other adverse reactions will occur in both groups.88 patients are grade I and Ⅱadverse reactions,and the incidence of fatigue,nausea,vomiting and anorexia in DEB-TACE group is lower than that in CTACE group,the difference was statistically significant(P<0.05).There was no statistical difference in preoperative liver function indexes between the two groups(P>0.05).The liver function index of patients in DEB-TACE group decreased 4-6 weeks after operation compared with 1 week after operation,and the difference was statistically significant compared with CTACE(P<0.05).There was no significant difference in renal function between the two groups before and after operation(P>0.05).There was no significant difference in AFP level between the two groups before operation(P>0.05).4-6 weeks after operation,AFP value in DEB-TACE group decreased,which was statistically significant compared with preoperative and CTACE groups(p<0.05).Conclusion:1.Compared with CTACE,DEB-TACE group has better short-term efficacy and higher tumor necrosis rate in treating advanced primary liver cancer.It has laid a good foundation for comprehensive treatment.2.The incidence rate of adverse reactions and complications of DEBTACE is lower than CTACE.Therefore,DEB-TACE is considered to be safer in clinical treatment of advanced primary liver cancer and can be widely used in clinical practice.